atai Life Sciences announces Phase 2 study of EMP-01 for social anxiety disorder, with results expected in Q1 2026. atai Life Sciences has announced the dosing of the first patient in a Phase 2 study ...
EMP-01 demonstrated a large, clinically meaningful reduction in patient-reported SAD symptoms at Day 43: placebo-adjusted LSMD -11.5 points (p=0.002) on SPIN; placebo-adjusted LSMD -15.6 points ...
NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical‑stage biotechnology company on a mission to transform patient outcomes by ...
NEW YORK and BERLIN, May 13, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective ...
Thank you for standing by. My name is Amy, and I will be your operator for today. At this time, I would like to welcome everyone to the AtaiBeckley EMP-01 Phase IIa Topline Data Conference Call.
EMP-01 met its primary objective on safety and tolerability, demonstrating a generally favorable and manageable safety and tolerability profile EMP-01 demonstrated a clinically meaningful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results